Form 4: Oragenics Inc. Director Kimberly M. Murphy Acquires Options

Director Kimberly M. Murphy acquired options to purchase 27,083 shares of Oragenics Inc. common stock on September 19, 2024.

Summary

• On September 19, 2024, Kimberly M. Murphy, a director of Oragenics Inc., was granted options to purchase 27,083 shares of the company's common stock.
• The options were awarded under the company's 2021 Equity Incentive Plan, as amended, as part of the non-employee director compensation program.
• The exercise price of the options is $0.48, which is the closing price of Oragenics' stock on the grant date.
• The options vest immediately and expire on September 19, 2034.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants to a director. It's neutral in sentiment, reflecting standard compensation practices.

Positives

• The immediate vesting of the options could incentivize the director to work towards the company's success.
• The grant aligns the director's interests with those of the shareholders.

Future Outlook

There is no specific future outlook provided in this document.

Industry Context

This is a standard Form 4 filing related to director compensation, which is common in publicly traded companies. The granting of stock options is a typical method to align the interests of directors with those of shareholders.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a common practice among publicly traded companies to align their interests with shareholders.
• The specific number of options granted and the exercise price are company-specific and depend on factors such as company size, stock performance, and director compensation policies.
• Comparable companies in the biotechnology sector, such as Novavax or Moderna, also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The granting of options to a director can positively impact shareholders by aligning the director's interests with the company's long-term success.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Oragenics Inc, Director, Kimberly M Murphy, Options, Equity Incentive Plan, Beneficial Ownership, Form 4, OGEN